New Depot Antipsychotics

New long-acting (depot) antipsychotics were approved in 2015: Aristada and Invega Trinza. This practical guide from the Psychopharmacology Institute summarizes the essentials for prescribers.

Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers

1 Advantages and disadvantages of long-acting antipsychotics
1.1 Potential advantages
1.2 Potential disadvantages
2 Clinical questions answered
3 Tables summarizing individual agents
3.1 First-generation antipsychotics available as long-acting injectable medications
3.2 Second-generation antipsychotics available as long-acting injectable medications
4 Practical considerations
4.1 Abilify Mantenna
4.2 Aristada
4.3 Zyprexa Relprevv
4.4 Invega Sustenna
4.5 Invega Trinza
4.6 Risperdal Consta

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations.¬†
  • Practical tips for mental health professionals.




Are you a visual learner interested in learning psychopharmacology? Click here to get our videos